| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324189 | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May, 2025
(1 year, 8 months from now) | |
|
US8324189 (Pediatric) | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Nov, 2025
(2 years from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(4 years from now) | |
Zometa is owned by Novartis.
Zometa contains Zoledronic Acid.
Zometa has a total of 3 drug patents out of which 0 drug patents have expired.
Zometa was authorised for market use on 20 August, 2001.
Zometa is available in injectable;intravenous dosage forms.
Zometa can be used as multiple myeloma; bone metastases; hypercalcemia of malignancy.
The generics of Zometa are possible to be released after 05 February, 2028.
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 20 August, 2001
Treatment: Multiple myeloma; Bone metastases; Hypercalcemia of malignancy
Dosage: INJECTABLE;INTRAVENOUS
ZOMETA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic